Logotype for Radiopharm Theranostics Limited

Radiopharm Theranostics (RAD) investor relations material

Radiopharm Theranostics Investor Presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Radiopharm Theranostics Limited
Investor Presentation summary19 Oct, 2025

Clinical pipeline and trial progress

  • Six clinical-stage programs targeting brain metastases, pancreatic cancer, HER2+ and PD-L1+ solid tumors, B7-H3, and KLK3, with two diagnostics and four therapeutics in trials by December 2025.

  • Phase 2b imaging study for brain metastases (RAD101) is ongoing, with 12/30 patients dosed and completion expected in Q1 2026; early data show increased metabolic activity in suspected relapses.

  • Phase 1 trials for HER2+ (RAD202) and PD-L1+ (RAD204) solid tumors are enrolling, with favorable safety profiles and early signs of disease stabilization in heavily pretreated patients.

  • Phase 1 imaging trial for pancreatic cancer (RAD301) is ongoing, with high sensitivity for detecting primary and metastatic lesions; 6/9 patients dosed as of October 2025.

Commercial potential and market positioning

  • RAD101 is projected to reach over $500 million in annual US sales, with a peak market share of 94% by year 8, targeting a large unmet need in post-SRS brain metastasis imaging.

  • No direct competitors identified for RAD101 in brain metastasis PET imaging; other pipeline assets address multi-billion dollar markets in HER2+ and PD-L1+ cancers.

  • Strategic partnership with Lantheus includes a 12% equity stake and co-development agreement, with Lantheus funding clinical development costs.

Financials and capital raising

  • Approximately A$40 million is being raised via a two-tranche placement and share purchase plan at A$0.03 per share, an 18.9% discount to the last close.

  • Post-raise, pro forma cash balance is expected to be A$59 million, fully funding clinical programs through multiple near-term catalysts and into 2027.

  • Lantheus committed to participate for US$5 million (A$7.6 million); Bell Potter, Leerink Partners, and B. Riley Securities are managing the offer.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Radiopharm Theranostics earnings date

Logotype for Radiopharm Theranostics Limited
Q1 202628 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Radiopharm Theranostics earnings date

Logotype for Radiopharm Theranostics Limited
Q1 202628 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Radiopharm Theranostics Limited is a biotechnology company focused on the development of radiopharmaceutical products for the diagnosis and treatment of cancer. The company specializes in theranostics, combining therapeutic and diagnostic capabilities into a single platform. Its pipeline includes targeted radiopharmaceuticals designed to deliver precision treatments while enabling imaging for monitoring disease progression. The company is headquartered in Melbourne, Australia, and its shares are listed on the ASX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage